Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
Commentary|Articles|February 27, 2026
Revised Childhood Immunization Schedule Lacks Transparency: Former ACIP Member Noel T. Brewer, PhD
Author(s)Brooke McCormick, Noel T. Brewer, PhD
Fact checked by: Maggie L. Shaw
Noel T. Brewer, PhD, former ACIP member, warns that the CDC's reduction from 17 to 11 recommended immunizations lacks transparency, which may lower uptake.
Advertisement
Advertisement
Early last month, the CDC
Related to this article
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.
Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.
Advertisement
Advertisement